

# William E Gillanders

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2617262/publications.pdf>

Version: 2024-02-01

44  
papers

4,064  
citations

257450

24  
h-index

276875

41  
g-index

48  
all docs

48  
docs citations

48  
times ranked

7746  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 529-541.	4.1	26
2	Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. <i>Genome Medicine</i> , 2021, 13, 56.	8.2	34
3	Cancer-associated mutations reveal a novel role for EpCAM as an inhibitor of cathepsin-L and tumor cell invasion. <i>BMC Cancer</i> , 2021, 21, 541.	2.6	5
4	Personalized DNA neoantigen vaccine in combination with plasmid IL-12 for the treatment of a patient with anaplastic astrocytoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14561-e14561.	1.6	0
5	Staging of the Axilla in Breast Cancer and the Evolving Role of Axillary Ultrasound. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 311-323.	1.8	6
6	Immunogenomic Profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 187-202.	2.5	24
7	Challenges targeting cancer neoantigens in 2021: a systematic literature review. <i>Expert Review of Vaccines</i> , 2021, 20, 827-837.	4.4	13
8	Functional Implications of the Dynamic Regulation of EpCAM during Epithelial-to-Mesenchymal Transition. <i>Biomolecules</i> , 2021, 11, 956.	4.0	30
9	Impact of consensus guidelines for breast-conserving surgery in patients with ductal carcinoma in situ. <i>Cancer Reports</i> , 2021, , e1502.	1.4	3
10	Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6761-6771.	7.0	33
11	Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR+ breast cancer and negative axillary ultrasound. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 251-262.	2.5	6
12	cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. <i>Nature</i> , 2020, 584, 624-629.	27.8	298
13	Cancer vaccines: shared tumor antigens return to the spotlight. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 251.	17.1	21
14	pVACtools: A Computational Toolkit to Identify and Visualize Cancer Neoantigens. <i>Cancer Immunology Research</i> , 2020, 8, 409-420.	3.4	132
15	Best practices for bioinformatic characterization of neoantigens for clinical utility. <i>Genome Medicine</i> , 2019, 11, 56.	8.2	146
16	Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. <i>OncImmunity</i> , 2019, 8, e1561106.	4.6	50
17	Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. <i>Oncotarget</i> , 2019, 10, 4761-4775.	1.8	45
18	Development of an adenovirus vector vaccine platform for targeting dendritic cells. <i>Cancer Gene Therapy</i> , 2018, 25, 27-38.	4.6	27

#	ARTICLE	IF	CITATIONS
19	Targeting both tumour-associated CXCR2 <sup>+</sup> neutrophils and CCR2 <sup>+</sup> macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. <i>Gut</i> , 2018, 67, 1112-1123.	12.1	334
20	WDFY4 is required for cross-presentation in response to viral and tumor antigens. <i>Science</i> , 2018, 362, 694-699.	12.6	216
21	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4055-4065.	7.0	243
22	Cost Analysis of a Surgical Consensus Guideline in Breast-Conserving Surgery. <i>Journal of the American College of Surgeons</i> , 2017, 225, 294-301.	0.5	22
23	Breast Cancer Neoantigens Can Induce CD8 <sup>+</sup> T-Cell Responses and Antitumor Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 516-523.	3.4	74
24	Personalized cancer vaccines: Targeting the cancer mutanome. <i>Vaccine</i> , 2017, 35, 1094-1100.	3.8	63
25	Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 NO Breast Cancer and Normal Axillary Ultrasound. <i>Journal of the American College of Surgeons</i> , 2016, 223, 399-407.	0.5	30
26	Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer. <i>Annals of Surgery</i> , 2016, 264, 1098-1102.	4.2	53
27	Lymphovascular space invasion and lack of downstaging after neoadjuvant chemotherapy are strong predictors of adverse outcome in young women with locally advanced breast cancer. <i>Cancer Medicine</i> , 2016, 5, 230-238.	2.8	5
28	Mammaglobin-A is a target for breast cancer vaccination. <i>Oncolmunology</i> , 2016, 5, e1069940.	4.6	26
29	Developing a clinical development paradigm for translation of a mammaglobin-A DNA vaccine. <i>Immunotherapy</i> , 2015, 7, 709-711.	2.0	1
30	Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5964-5975.	7.0	70
31	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , 2014, 515, 577-581.	27.8	1,705
32	EpCAM Modulates NF- $\kappa$ B Signaling and Interleukin-8 Expression in Breast Cancer. <i>Molecular Cancer Research</i> , 2013, 11, 418-426.	3.4	29
33	Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4 <sup>+</sup> ICOS <sup>+</sup> T cells. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 109-118.	2.5	53
34	Cross-dressed CD8 <sup>+</sup> /CD103 <sup>+</sup> dendritic cells prime CD8 <sup>+</sup> T cells following vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12716-12721.	7.1	63
35	Identification of HLA-A24-restricted CD8 <sup>+</sup> cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancer-associated antigen. <i>Human Immunology</i> , 2012, 73, 11-16.	2.4	10
36	Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. <i>Breast Cancer Research</i> , 2011, 13, R124.	5.0	37

#	ARTICLE	IF	CITATIONS
37	Identification of immunodominant HLA-B7-restricted CD8+ cytotoxic T cell epitopes derived from mammaglobin-A expressed on human breast cancers. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 81-89.	2.5	10
38	Cancer Genome Sequencing and Its Implications for Personalized Cancer Vaccines. <i>Cancers</i> , 2011, 3, 4191-4211.	3.7	22
39	Single-Chain HLA-A2 MHC Trimers That Incorporate an Immunodominant Peptide Elicit Protective T Cell Immunity against Lethal West Nile Virus Infection. <i>Journal of Immunology</i> , 2010, 184, 4423-4430.	0.8	45
40	Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens. <i>Vaccine</i> , 2010, 28, 1911-1918.	3.8	16
41	Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 305-314.	2.5	15
42	Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 453-463.	2.5	21
43	Oral contraceptive use and the risk of early-onset breast cancer in carriers and noncarriers of <i>BRCA1</i> and <i>BRCA2</i> mutations. <i>Women's Oncology Review</i> , 2005, 5, 127-128.	0.0	0
44	Pollock: Fishing for Cell States. <i>Bioinformatics Advances</i> , 0, , .	2.4	0